IP Library › Granted Patent US 7,504,109
Granted Patent B2
US 7,504,109 · App. 11/133,346 · Granted Mar 17, 2009

Influenza hemagglutinin and neuraminidase variants

Assignees: MedImmune, LLC; The United States of America as Represented by The Department of Health Services, National Institute of Health
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,504,109
App. No.
11/133,346
Granted
Mar 17, 2009
Kind
B2
Abstract

Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.

Claims (19)

1. A reassortant influenza virus, wherein said virus comprises at least 6 internal genome segments from A/Ann Arbor/6/60 and at least one genome segment comprising a nucleic acid encoding a hemagglutinin polypeptide comprising the amino acid sequence of SEQ ID NO:15; wherein said nucleic acid comprises the nucleotide sequence of SEQ ID NO:5.

2. An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of claim 1 .

3. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the reassortant influenza virus of claim 1 in a physiologically effective carrier.

4. A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject, the virus of claim 1 in an amount effective to produce an immunogenic response against the viral infection.

5. The method of claim 4 , wherein the subject is a human.

6. The immunogenic composition of claim 2 , wherein said reassortant influenza virus further comprises a neuramidinase genome segment comprising a nucleic acid encoding a neuramidinase polypeptide selected from the group consisting of: the polypeptides of SEQ ID NOs: 12, 14, 16, 18, and 20.

7. A live attenuated influenza vaccine comprising the composition of claim 2 .

8. A split virus or killed virus vaccine comprising the composition of claim 2 .

9. A live attenuated influenza vaccine comprising the composition of claim 6 .

10. A split virus or killed virus vaccine comprising the composition of claim 6 .

11. A method for producing influenza viruses in cell culture, the method comprising:

i) introducing into a population of host cells a plurality of vectors comprising nucleic acid sequences corresponding to at least 6 internal genome segments of the influenza strain A/Ann Arbor/6/60; and at least one genome segment comprising a nucleic acid encoding a hemagglutinin polypeptide comprising the amino acid sequence of SEO ID NO:15; wherein said nucleic acid comprises the nucleotide sequence of SEO ID NO:5,

ii) culturing the population of host cells at a temperature less than or equal to 35° C.; and,

iii) recovering a plurality of influenza viruses.

12. The immunogenic composition of claim 6 , wherein said neuramidinase polypeptide comprises the amino acid sequence of SEQ ID NO:16.

13. The immunogenic composition of claim 12 , wherein said neuramidinase polypeptide comprising the amino acid sequence of SEQ ID NO:16 is encoded by a nucleic acid comprising the nucleotide sequence of SEQ ID NO:6.

14. The method of claim 11 , wherein said plurality of vectors further comprise a nucleic acid sequence corresponding to a neuramidinase genome segment encoding a neuramidinase polypeptide selected from the group consisting of: SEQ ID NO:12, 14, 16, and 18.

15. The method of claim 14 , wherein said neuramidinase polypeptide comprises the amino acid sequence of SEQ ID NO:16.

16. The method of claim 15 , wherein said neuramidinase polypeptide comprising the amino acid sequence of SEQ ID NO:16 is encoded by a nucleic acid comprising the nucleotide sequence of SEQ ID NO:6.

Assignments (5)
CHANGE OF NAME Recorded Aug 15, 2008
From: MEDIMMUNE, INC.
To: MEDIMMUNE, LLC.
Reel/Frame 021400/0954 →
CHANGE OF NAME Recorded Aug 15, 2008
From: MEDIMMUNE VACCINES, INC.
To: MEDIMMUNE, INC.
Reel/Frame 021400/0990 →
CHANGE OF NAME Recorded Jun 10, 2008
From: MEDIMMUNE VACCINES, INC.; MEDIMMUNE, INC.
To: MEDIMMUNE, LLC
Reel/Frame 021069/0901 →
CORRECTIVE ASSIGNMENT TO CORRECT THE TO CORRECT FIRST ASSIGNEE'S NAME; AND TO CORRECT EXECUTION DATE FOR INVENTOR, GEORGE KEMBLE PREVIOUSLY RECORDED ON REEL 016838 FRAME 0616. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 14, 2008
From: YANG, CHIN-FEN; KEMBLE, GEORGE; SUBBARAO, KANTA; MURPHY, BRIAN
To: MEDIMMUNE VACCINES, INC.; GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH SERVICES, NATIONAL INSTITTUTE OF HEALTH
Reel/Frame 020359/0084 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2005
From: YANG, CHIN-FEN; KEMBLE, GEORGE; SUBBARAO, KANTA; MURPHY, BRIAN
To: MEDIMMUNE, INC.; GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH SERVICES, NATIONAL INSTITUTE OF HEALTH, THE
Reel/Frame 016838/0616 →
Continuity (3)
Provisional Application 6057455300 · May 25, 2004
Provisional Application 6065755400 · Feb 28, 2005
Related Publication 20060008473A1 · Jan 12, 2006